FDA Grants Full Approval to Novel Alzheimer's Drug, Igniting Hope Amidst Controversy

The FDA has granted full approval to the Alzheimer's drug Leqembi, making it eligible for coverage by Medicare and other insurance plans. Leqembi is the first drug shown to modestly slow cognitive decline in Alzheimer's patients. However, concerns remain about its efficacy and potential risks, including brain swelling and bleeding. Medicare will cover the drug but will require enrollment in a federal registry to monitor its real-world safety and effectiveness. The cost of Leqembi, priced at $26,500 for a year's supply, has raised concerns about the program's finances.